Accelerate Diagnostics, Inc. (AXDX)

NASDAQ: AXDX · IEX Real-Time Price · USD
0.748
-0.002 (-0.21%)
Dec 5, 2022 3:59 PM EST - Market closed
-0.21%
Market Cap 74.32M
Revenue (ttm) 13.12M
Net Income (ttm) -70.50M
Shares Out 87.01M
EPS (ttm) -1.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 295,236
Open 0.79
Previous Close 0.75
Day's Range 0.74 - 0.79
52-Week Range 0.5 - 5.59
Beta 1.24
Analysts Buy
Price Target 2.04 (+171.1%)
Earnings Date Nov 14, 2022

About AXDX

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic sus... [Read more]

Industry Life Sciences Tools & Services
IPO Date Nov 18, 1996
CEO John Phillips
Employees 220
Stock Exchange NASDAQ
Ticker Symbol AXDX
Full Company Profile

Financial Performance

In 2021, AXDX's revenue was $11.78 million, an increase of 5.53% compared to the previous year's $11.17 million. Losses were -$77.70 million, -0.65% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for AXDX stock is "Buy." The 12-month stock price forecast is 2.04, which is an increase of 171.06% from the latest price.

Price Target
$2.04
(171.06% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Accelerate Diagnostics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lo...

Boston, Massachusetts--(Newsfile Corp. - November 15, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have los...

2 weeks ago - Newsfile Corp

Accelerate Diagnostics Reports Third Quarter 2022 Financial Results

TUCSON, Ariz. , Nov. 14, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022.

2 weeks ago - PRNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Accelerate Diagnostics, Inc. - AXDX

NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Accelerate Diagnostics, Inc. ("Accelerate" or the "Company") (NASDAQ: AXDX).  Such investors are ...

3 weeks ago - PRNewsWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Accelerate Diagnostics, ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Accelerate Diagnost...

1 month ago - Business Wire

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Accelerate Diagnostics,...

Los Angeles, California--(Newsfile Corp. - October 27, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acc...

1 month ago - Newsfile Corp

The Law Offices of Frank R. Cruz Announces Investigation of Accelerate Diagnostics, Inc. (AXDX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R.

1 month ago - Business Wire

Accelerate Diagnostics Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lo...

Boston, Massachusetts--(Newsfile Corp. - October 26, 2022) - Block & Leviton is investigating Accelerate Diagnostics, Inc. (NASDAQ: AXDX) for potential securities law violations. Investors who have lost...

1 month ago - Newsfile Corp

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. a...

Los Angeles, California--(Newsfile Corp. - October 26, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Acc...

1 month ago - Newsfile Corp

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securities Class A...

NEW YORK , Oct. 26, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics,...

1 month ago - PRNewsWire

ACCELERATE DIAGNOSTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Accelerate Diagnostics, Inc. on Behalf of ...

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C.

1 month ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc....

LOS ANGELES--(BUSINESS WIRE)---- $AXDX #AXDX--The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

1 month ago - Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Accelerate Diagnostics, Inc. Investors to Inquire About Securi...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Accelerate Diagnostics, Inc. (NASDAQ:...

1 month ago - Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. an...

LOS ANGELES--(BUSINESS WIRE)---- $AXDX #AXDX--The Schall Law Firm Announces it is Investigating Claims Against Accelerate Diagnostics, Inc. and Encourages Investors with Losses to Contact the Firm

1 month ago - Business Wire

Accelerate Diagnostics scheduled call to review 2022 third quarter results

TUCSON, Ariz. , Oct. 24, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, November 14, 2022, at 4:30 p.m.

1 month ago - PRNewsWire

Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock

TUCSON, Ariz. , Aug. 18, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced the pricing of an underwritten public offering of 17,500,000 shares o...

3 months ago - PRNewsWire

Accelerate Diagnostics Announces Proposed Public Offering of Common Stock

TUCSON, Ariz. , Aug. 17, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) ("Accelerate Diagnostics") today announced that it has commenced an underwritten public offering of shares of it...

3 months ago - PRNewsWire

Accelerate Diagnostics Reports Second Quarter 2022 Financial Results

TUCSON, Ariz. , Aug. 15, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022.

3 months ago - PRNewsWire

BD, Accelerate Diagnostics Announce Global Commercial Collaboration

Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide FRANKLIN LAKES, N.J. and TUCSON, Ariz.

Other symbols: BDX
3 months ago - PRNewsWire

Accelerate Diagnostics scheduled call to review 2022 second quarter results

TUCSON, Ariz. , July 25, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Monday, August 15, 2022, at 4:30 p.m.

4 months ago - PRNewsWire

Accelerate Diagnostics announces commercialization in Europe of its Accelerate Arc™ system having completed IVDR regi...

- Commercialization of the Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial identification (ID) for positive blood cultures acro...

4 months ago - PRNewsWire

Accelerate Diagnostics to Participate in 42nd Annual William Blair Growth Stock Conference on June 7, 2022

TUCSON, Ariz. , May 23, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that Chief Executive Officer, Jack Phillips, will present at the 42nd Annual William Blair Growth...

6 months ago - PRNewsWire

Accelerate Diagnostics (AXDX) Reports Q1 Loss, Tops Revenue Estimates

Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 21.88% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Accelerate Diagnostics Reports First Quarter 2022 Financial Results

TUCSON, Ariz. , May 16, 2022 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022.

6 months ago - PRNewsWire

Accelerate Diagnostics announces commercialization of its Accelerate Arc™ system having completed IVD registration wi...

Commercialization of Accelerate Arc system, which includes the Accelerate Arc Module and BC kit, unlocks the path to automated, rapid microbial ID for positive blood cultures across the large installed ...

6 months ago - PRNewsWire